These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 2512578)
1. Tumor suppression involves down-regulation of interleukin 3 expression in hybrids between autocrine mastocytoma and interleukin 3-dependent parental mast cells. Diamantis ID; Nair AP; Hirsch HH; Moroni C Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9299-302. PubMed ID: 2512578 [TBL] [Abstract][Full Text] [Related]
2. V-Ha-ras-dependent expression of interleukin-3 mRNA in premalignant PB-3c mast cells correlates with the formation of tumors without interleukin-3 gene rearrangements. Aebersold DM; Banholzer R; Backenstoss V; Hirsch HH; Moroni C Exp Hematol; 1997 May; 25(5):395-404. PubMed ID: 9168061 [TBL] [Abstract][Full Text] [Related]
3. Mast cells sensitive to v-H-ras transformation are hyperinducible for interleukin 3 expression and have lost tumor-suppressor activity. Nair AP; Hirsch HH; Moroni C Oncogene; 1992 Oct; 7(10):1963-72. PubMed ID: 1408138 [TBL] [Abstract][Full Text] [Related]
4. A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production. Nair AP; Diamantis ID; Conscience JF; Kindler V; Hofer P; Moroni C Mol Cell Biol; 1989 Mar; 9(3):1183-90. PubMed ID: 2498644 [TBL] [Abstract][Full Text] [Related]
5. Suppressible and nonsuppressible autocrine mast cell tumors are distinguished by insertion of an endogenous retroviral element (IAP) into the interleukin 3 gene. Hirsch HH; Nair AP; Moroni C J Exp Med; 1993 Aug; 178(2):403-11. PubMed ID: 8340751 [TBL] [Abstract][Full Text] [Related]
6. Tumor-promoting phorbol ester and activated Ha-ras synergistically reduce the interleukin 3 requirement in a mast cell line. Imber R; Fabbro D Cancer Res; 1991 Jan; 51(2):632-8. PubMed ID: 1985780 [TBL] [Abstract][Full Text] [Related]
7. Multistage mastocytoma model characterized by autocrine IL-3 production. Moroni C; Diamantis ID; Wodnar-Filipowicz A; Nair AP Haematol Blood Transfus; 1989; 32():407-10. PubMed ID: 2516498 [No Abstract] [Full Text] [Related]
8. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Stoecklin G; Gross B; Ming XF; Moroni C Oncogene; 2003 Jun; 22(23):3554-61. PubMed ID: 12789264 [TBL] [Abstract][Full Text] [Related]
9. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Brown MA; Pierce JH; Watson CJ; Falco J; Ihle JN; Paul WE Cell; 1987 Aug; 50(5):809-18. PubMed ID: 3497723 [TBL] [Abstract][Full Text] [Related]
14. Regulation of interleukin 3 mRNA expression in mast cells occurs at the posttranscriptional level and is mediated by calcium ions. Wodnar-Filipowicz A; Moroni C Proc Natl Acad Sci U S A; 1990 Jan; 87(2):777-81. PubMed ID: 2105489 [TBL] [Abstract][Full Text] [Related]
15. Differential dependence of the tumorigenicity of chemically transformed rat liver epithelial cells on autocrine production of transforming growth factor alpha. Duddy SK; Earp HS; Russell WE; Smith GJ; Grisham JW Cell Growth Differ; 1995 Mar; 6(3):251-61. PubMed ID: 7794793 [TBL] [Abstract][Full Text] [Related]
16. [Massive apoptosis in P815 mastocytoma in vivo induced by interleukin 2 gene transduction]. Guo N; Li X; Liu X Zhonghua Bing Li Xue Za Zhi; 1996 Oct; 25(5):284-7. PubMed ID: 9388873 [TBL] [Abstract][Full Text] [Related]
17. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Su ZZ; Austin VN; Zimmer SG; Fisher PB Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744 [TBL] [Abstract][Full Text] [Related]
18. Subthreshold IKK activation modulates the effector functions of primary mast cells and allows specific targeting of transformed mast cells. Drube S; Weber F; Loschinski R; Beyer M; Rothe M; Rabenhorst A; Göpfert C; Meininger I; Diamanti MA; Stegner D; Häfner N; Böttcher M; Reinecke K; Herdegen T; Greten FR; Nieswandt B; Hartmann K; Krämer OH; Kamradt T Oncotarget; 2015 Mar; 6(7):5354-68. PubMed ID: 25749030 [TBL] [Abstract][Full Text] [Related]